NewAmsterdam Pharma Company NV [NASDAQ: NAMS] gained 41.41% or 7.67 points to close at $26.19 with a heavy trading volume of 9312798 shares.
The daily chart for NAMS points out that the company has recorded 31.87% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 431.75K shares, NAMS reached to a volume of 9312798 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about NewAmsterdam Pharma Company NV [NAMS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NAMS shares is $41.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NAMS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for NewAmsterdam Pharma Company NV shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 15, 2024. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on March 14, 2024, representing the official price target for NewAmsterdam Pharma Company NV stock. Previously, the target price had yet another raise to $30, while Guggenheim analysts kept a Buy rating on NAMS stock.
The Average True Range (ATR) for NewAmsterdam Pharma Company NV is set at 1.69 The Price to Book ratio for the last quarter was 6.37, with the Price to Cash per share for the same quarter was set at 4.58.
Trading performance analysis for NAMS stock
NewAmsterdam Pharma Company NV [NAMS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.08. With this latest performance, NAMS shares gained by 8.58% in over the last four-week period, additionally plugging by 31.87% over the last 6 months – not to mention a rise of 167.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NAMS stock in for the last two-week period is set at 69.87, with the RSI for the last a single of trading hit 75.52, and the three-weeks RSI is set at 66.86 for NewAmsterdam Pharma Company NV [NAMS]. The present Moving Average for the last 50 days of trading for this stock 20.02, while it was recorded at 19.88 for the last single week of trading, and 19.44 for the last 200 days.
NewAmsterdam Pharma Company NV [NAMS]: A deeper dive into fundamental analysis
NewAmsterdam Pharma Company NV’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.61 and a Current Ratio set at 10.61.
An analysis of Institutional ownership at NewAmsterdam Pharma Company NV [NAMS]
There are presently around $90.31%, or 90.54%% of NAMS stock, in the hands of institutional investors.
